Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Paliperidone Palmitate Injection (3M) in Schizophrenia
NCT07493551Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Maximum Steady-State Plasma Concentration and Area Under the Curve at Steady State. Started Oct 2024; status: recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07493551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493551.